Health Care·Pharmaceuticals·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.55 | N/A | +17.91% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.55 | N/A | +17.91% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about future developments. They are focused on their pipeline and operational strategies, despite not providing specific guidance.
Management highlighted ongoing efforts to advance their pipeline.
They emphasized the importance of upcoming clinical milestones.
There was a focus on maintaining operational efficiency.
This earnings report indicates that Terns Pharmaceutical is still in the early stages of its growth, with a notable EPS surprise despite not reporting revenue figures. The stock reacted negatively, declining by 0.66%, likely due to the lack of revenue data and forward guidance. Investors may be looking for clearer indicators of future performance in upcoming quarters.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AST SPACEMOBILE INC Class A
May 16, 2022